110 related articles for article (PubMed ID: 23000262)
1. Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer.
Stiles BM; Nasar A; Mirza F; Paul S; Lee PC; Port JL; McGraw TE; Altorki NK
Ann Thorac Surg; 2013 Feb; 95(2):397-403; discussion 404. PubMed ID: 23000262
[TBL] [Abstract][Full Text] [Related]
2. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V
J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769
[TBL] [Abstract][Full Text] [Related]
3. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
Al-Sarraf N; Gately K; Lucey J; Aziz R; Doddakula K; Wilson L; McGovern E; Young V
Eur J Cardiothorac Surg; 2008 Oct; 34(4):892-7. PubMed ID: 18722132
[TBL] [Abstract][Full Text] [Related]
4. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
[TBL] [Abstract][Full Text] [Related]
5. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
Lopez Guerra JL; Gladish G; Komaki R; Gomez D; Zhuang Y; Liao Z
J Nucl Med; 2012 Feb; 53(2):225-33. PubMed ID: 22241911
[TBL] [Abstract][Full Text] [Related]
6. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
Zhang H; Wroblewski K; Pu Y
Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of the PET parameter maximum standardized uptake value in non small cell lung cancer: analysis in tumour of diameter ≥ and <25 mm.
Pelosi E; Billè A; Skanjeti A; Errico L; Arena V; Ardissone F; Borasio P; Mancini M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):72-80. PubMed ID: 20539268
[TBL] [Abstract][Full Text] [Related]
14. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
[TBL] [Abstract][Full Text] [Related]
15. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT.
Xu ZQ; Xie LJ; Fan W; Duan XB; Cheng MH
Nucl Med Commun; 2014 May; 35(5):466-71. PubMed ID: 24535381
[TBL] [Abstract][Full Text] [Related]
17. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
Trister AD; Pryma DA; Xanthopoulos E; Kucharczuk J; Sterman D; Rengan R
Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
